Literature DB >> 20526843

Survival of bifidobacteria in adult intestinal tract.

M Grmanová1, E Vlková, V Rada, I Homutová.   

Abstract

The "cocktail" of human origin rifampicin-resistant bifidobacteria (RRBs) and RRBs from commercial products was administrated to 9 volunteers aged from 22 to 46 years and the survival ability in gastrointestinal tract of these strains was determined. Bifidobacteria represented 0-8 % of total anaerobes detected in gastrointestinal tract of volunteers before the administration of probiotic strains. After the administration of probiotics, bifidobacterial counts increased to 16 % of total bacterial counts. RRBs formed 9-44 % of total counts of bifidobacteria. Then, the counts of RRBs decreased at day 7 after administration, and they were not detected after 14 d. In our study, suitable probiotic bifidobacterial strains for human should be chosen on the basic of in vitro test but the results showed that no strain was able to colonize human tract permanently.

Entities:  

Mesh:

Year:  2010        PMID: 20526843     DOI: 10.1007/s12223-010-0042-5

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  18 in total

1.  Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant of Bifidobacterium longum SBT2928: its long-term survival and effect on the intestinal microflora and metabolism.

Authors:  S Fujiwara; Y Seto; A Kimura; H Hashiba
Journal:  J Appl Microbiol       Date:  2001-01       Impact factor: 3.772

Review 2.  Probiotics in human medicine.

Authors:  R Fuller
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

Review 3.  Probiotics: determinants of survival and growth in the gut.

Authors:  A Bezkorovainy
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

4.  Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction.

Authors:  P Brigidi; B Vitali; E Swennen; L Altomare; M Rossi; D Matteuzzi
Journal:  Syst Appl Microbiol       Date:  2000-10       Impact factor: 4.022

5.  Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers.

Authors:  T Matsuki; K Watanabe; R Tanaka; M Fukuda; H Oyaizu
Journal:  Appl Environ Microbiol       Date:  1999-10       Impact factor: 4.792

6.  Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants.

Authors:  J P Langhendries; J Detry; J Van Hees; J M Lamboray; J Darimont; M J Mozin; M C Secretin; J Senterre
Journal:  J Pediatr Gastroenterol Nutr       Date:  1995-08       Impact factor: 2.839

7.  The intestinal microflora of childhood patients with indicated celiac disease.

Authors:  J Kopecný; J Mrázek; K Fliegerová; P Frühauf; L Tucková
Journal:  Folia Microbiol (Praha)       Date:  2008-07-27       Impact factor: 2.099

8.  Auto-aggregation and co-aggregation ability in bifidobacteria and clostridia.

Authors:  E Vlková; V Rada; M Smehilová; J Killer
Journal:  Folia Microbiol (Praha)       Date:  2008-07-27       Impact factor: 2.099

9.  Impact of Bifidobacterium longum on human fecal microflora.

Authors:  Y Benno; T Mitsuoka
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

10.  Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk.

Authors:  Y Bouhnik; P Pochart; P Marteau; G Arlet; I Goderel; J C Rambaud
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

View more
  1 in total

1.  In vitro utilization of gold and green kiwifruit oligosaccharides by human gut microbial populations.

Authors:  Shanthi G Parkar; Doug Rosendale; Gunaranjan Paturi; Thanuja D Herath; Halina Stoklosinski; Janet E Phipps; Duncan Hedderley; Juliet Ansell
Journal:  Plant Foods Hum Nutr       Date:  2012-09       Impact factor: 3.921

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.